Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Estradiol Patch Real-World Response Rate: What Clinical Data and Patient Reports Actually Show

By
Published Updated Last reviewed
5 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Approved uses on patch labels / hot flashes, vulvar and vaginal atrophy, hypoestrogenism, osteoporosis prevention [1][2]
  • Starting doses / Climara 0.025 mg/day once weekly; Vivelle-Dot 0.0375 mg/day twice weekly [1][2]
  • Weekly hot flushes, oral hormone therapy vs placebo / 17.92 fewer, a 75% reduction (95% CI 64.3 to 82.3) [3]
  • Lumbar spine bone density, transdermal trial / median +5.3% vs +0.2% (P=0.007) [4]
  • Breast pain, Climara label table / 5%, 8% and 29% at 0.025, 0.05 and 0.1 mg/day vs 4% placebo [1]

What the patch labels say

Estradiol patches are FDA-approved for moderate to severe vasomotor symptoms due to menopause, moderate to severe vulvar and vaginal atrophy, hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevention of postmenopausal osteoporosis [1][2]. Climara starts at 0.025 mg per day once weekly; Vivelle-Dot starts at 0.0375 mg per day twice weekly [1][2].

The Climara and Vivelle-Dot labels still carry the longer boxed warning covering endometrial cancer, cardiovascular disorders, probable dementia and breast cancer [1][2].

Where the hot-flush percentages come from

A Cochrane meta-analysis pooled 24 double-blind, placebo-controlled trials of oral hormone therapy lasting at least three months, with 3,329 participants and follow-up of three months to three years [3]. Hormone therapy reduced weekly hot flush frequency by 17.92 flushes versus placebo (95% CI -22.86 to -12.99), a 75% reduction relative to placebo (95% CI 64.3 to 82.3), and reduced symptom severity (odds ratio 0.13, 95% CI 0.07 to 0.23) [3]. These are oral-therapy results, so they are not a patch response rate.

What the transdermal trials measured

The Climara label summarizes hot-flush trials of the patch in postmenopausal women (placebo n=72), with adverse reactions reported by dose [1]. Two other transdermal trials are described below: one measured bone density and fractures, while KEEPS-Cog measured cognition and mood [4][5].

In the bone trial, 75 postmenopausal women with established osteoporosis and vertebral fractures received patches delivering 0.1 mg of estradiol on days 1 to 21 of each 28-day cycle, alongside oral medroxyprogesterone on days 11 to 21, or placebo, for one year [4]. Median annual bone density change at the lumbar spine was +5.3% with estradiol versus +0.2% with placebo (P=0.007) [4].

In KEEPS-Cog, 211 recently postmenopausal women were assigned transdermal estradiol 50 mcg/day, 220 oral conjugated equine estrogens 0.45 mg/day, and 262 placebo, for up to four years; both hormone groups also took micronized progesterone for 12 days a month [5]. Treatment gave no cognitive benefit. On mood, transdermal estradiol was similar to placebo, while oral conjugated equine estrogens improved depression and anxiety scores [5].

Frequently asked questions

How much does oral hormone therapy reduce hot flashes?
A Cochrane meta-analysis of 24 double-blind trials in 3,329 women found oral hormone therapy cut weekly hot flush frequency by 17.92 flushes versus placebo, a 75% reduction (95% CI 64.3 to 82.3) [3]. That analysis covered oral therapy, not patches.
What did the transdermal bone trial find?
In the one-year bone trial, the estradiol-patch group also received oral medroxyprogesterone during part of each cycle; the comparison group received placebo. Lumbar spine bone density rose a median 5.3% versus 0.2% (P=0.007) [4].
Did transdermal estradiol improve mood or memory?
In KEEPS-Cog, 211 women were assigned transdermal estradiol, 220 oral conjugated equine estrogens, and 262 placebo [5]. Neither hormone regimen improved cognition. Transdermal estradiol was similar to placebo on mood, while oral conjugated equine estrogens improved depression and anxiety scores [5].

References

  1. U.S. National Library of Medicine, DailyMed. Climara estradiol transdermal system (Bayer) prescribing information. Climara estradiol transdermal system (Bayer) label
  2. U.S. National Library of Medicine, DailyMed. Vivelle-Dot estradiol transdermal system (Sandoz) prescribing information. Vivelle-Dot estradiol transdermal system (Sandoz) label
  3. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;2004(4):CD002978. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes
  4. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117(1):1-9. Treatment of postmenopausal osteoporosis with transdermal estrogen
  5. Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Med. 2015;12(6):e1001833; discussion e1001833. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study
Evidence overview for Estradiol Patch Real-World Response Rate: What Clinical Data and Patient Reports Actually Show